search
Endpoints News
Trends
- 1Analysts Argue WILLOW Trial Endpoint, Not Enpatoran, Failed●The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.
Commentary around Merck KGaA's enpatoran is challenging the framing of the WILLOW trial results, arguing the drug was not proven ineffective but that the trial's chosen endpoint failed to capture the treatment effect. The piece says the outcome measure, not the therapy itself, is what fell short, reigniting debate over how lupus clinical trials are designed and judged.
- 2Endpoints News Names 2026 Endpoints 11 Award Winners●Endpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startups
Endpoints News has announced the winners of its 2026 Endpoints 11 Awards, an annual list honoring the most promising startups in biotechnology. The awards spotlight early-stage biotech companies considered the most exciting in the industry, drawing attention from investors, researchers and life-science professionals tracking which emerging firms could shape the next wave of drug development.